share_log

6-K: Gsk and Zhifei Revise and Extend Strategic Vaccine Collaboration in China

6-K: Gsk and Zhifei Revise and Extend Strategic Vaccine Collaboration in China

6-K：GSK與智飛修訂並延長在中國的疫苗戰略合作
美股SEC公告 ·  12/05 19:04

Moomoo AI 已提取核心訊息

GSK and Zhifei have revised and extended their strategic vaccine collaboration in China. The Shingrix agreement is extended to 2034, with Zhifei gaining exclusive rights to import, distribute, and co-promote the vaccine in mainland China. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.Zhifei also agrees to explore a potential 10-year collaboration on GSK's RSV vaccine, Arexvy, in mainland China, subject to regulatory approval. This partnership aims to leverage Zhifei's extensive network of over 30,000 vaccination points to improve access to innovative adult vaccines in China.The collaboration targets a market of more than 500 million people in China, including 570 million over-50s by 2030 for Shingrix, and 297 million over-60s for potential RSV vaccination. This revised agreement addresses near-term macro environment challenges while aiming for long-term growth in China's vaccine market.
GSK and Zhifei have revised and extended their strategic vaccine collaboration in China. The Shingrix agreement is extended to 2034, with Zhifei gaining exclusive rights to import, distribute, and co-promote the vaccine in mainland China. The deal's potential value to GSK is £2.3bn over 2024-2029, though previously contracted minimum purchase levels no longer apply.Zhifei also agrees to explore a potential 10-year collaboration on GSK's RSV vaccine, Arexvy, in mainland China, subject to regulatory approval. This partnership aims to leverage Zhifei's extensive network of over 30,000 vaccination points to improve access to innovative adult vaccines in China.The collaboration targets a market of more than 500 million people in China, including 570 million over-50s by 2030 for Shingrix, and 297 million over-60s for potential RSV vaccination. This revised agreement addresses near-term macro environment challenges while aiming for long-term growth in China's vaccine market.
GSk和智飛修訂並擴大了在中國的戰略生物-疫苗合作關係。Shingrix協議延長至2034年，智飛獲得在中國大陸獨家進口、分銷和共同推廣該生物-疫苗的權利。該交易對GSk的潛在價值在2024年至2029年間爲23億英鎊，儘管以前合同中規定的最低購買水平不再適用。智飛還同意探索在中國大陸對GSK的RSV生物-疫苗Arexvy進行潛在的10年合作，具體仍需監管批准。此次合作旨在利用智飛超過30,000個接種點的廣泛網絡，以改善中國對創新成人生物-疫苗的獲取。此合作目標是覆蓋中國超過50000萬人口的市場，包括到2030年時57000萬50歲以上人群的Shingrix生物-疫苗，以及29700萬60歲以上人群的潛在RSV接種。這項修訂協議應對了短期宏觀環境的挑戰，同時旨在爲中國的生物-疫苗市場帶來長期增長。
GSk和智飛修訂並擴大了在中國的戰略生物-疫苗合作關係。Shingrix協議延長至2034年，智飛獲得在中國大陸獨家進口、分銷和共同推廣該生物-疫苗的權利。該交易對GSk的潛在價值在2024年至2029年間爲23億英鎊，儘管以前合同中規定的最低購買水平不再適用。智飛還同意探索在中國大陸對GSK的RSV生物-疫苗Arexvy進行潛在的10年合作，具體仍需監管批准。此次合作旨在利用智飛超過30,000個接種點的廣泛網絡，以改善中國對創新成人生物-疫苗的獲取。此合作目標是覆蓋中國超過50000萬人口的市場，包括到2030年時57000萬50歲以上人群的Shingrix生物-疫苗，以及29700萬60歲以上人群的潛在RSV接種。這項修訂協議應對了短期宏觀環境的挑戰，同時旨在爲中國的生物-疫苗市場帶來長期增長。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間